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Abstract
Background—In response to increasing opioid overdoses, US prevention efforts have focused 
on prescriber education and supply, demand and harm reduction strategies. Limited evidence 
informs which interventions are effective. We evaluated Project Lazarus, a centralised statewide 
intervention designed to prevent opioid overdose.
Methods—Observational intervention study of seven strategies. 74 of 100 North Carolina 
counties implemented the intervention. Dichotomous variables were constructed for each strategy 
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by county-month. Exposure data were: process logs, surveys, addiction treatment interviews, 
prescription drug monitoring data. Outcomes were: unintentional and undetermined opioid 
overdose deaths, overdose-related emergency department (ED) visits. Interrupted time-series 
Poisson regression was used to estimate rates during preintervention (2009–2012) and intervention 
periods (2013–2014). Adjusted IRR controlled for prescriptions, county health status and time 
trends. Time-lagged regression models considered delayed impact (0–6 months).
Results—In adjusted immediate-impact models, provider education was associated with lower 
overdose mortality (IRR 0.91; 95% CI 0.81 to 1.02) but little change in overdose-related ED visits. 
Policies to limit ED opioid dispensing were associated with lower mortality (IRR 0.97; 95% CI 
0.87 to 1.07), but higher ED visits (IRR 1.06; 95% CI 1.01 to 1.12). Expansions of medication-
assisted treatment (MAT) were associated with increased mortality (IRR 1.22; 95% CI 1.08 to 
1.37) but lower ED visits in time-lagged models.
Conclusions—Provider education related to pain management and addiction treatment, and ED 
policies limiting opioid dispensing showed modest immediate reductions in mortality. MAT 
expansions showed beneficial effects in reducing ED-related overdose visits in time-lagged 
models, despite an unexpected adverse association with mortality.
INTRODUCTION
Overdose deaths attributable to prescription opioid analgesics (OA) in the US increased by 
200% from 2000 to 2014.1 While OA non-medical use has remained steady or has slightly 
decreased in recent years, heroin use has increased,2 as has the use of potent illicitly 
manufactured opioids.34 This crisis is unparalleled in the US since the AIDS epidemic, and 
will require substantial changes to healthcare delivery and societal norms to reverse.
The White House Office of National Drug Control Policy (ONDCP) in 2015 (with updates 
in 2016) announced broad federal initiatives and funding to address the crisis.5 Among these 
are OA prescriber training, use of medication-assisted treatment (MAT), encouraging the use 
of prescription drug monitoring programmes (PDMPs) and expanding naloxone distribution. 
In addition, ONDCP has promoted community education, and other agencies have suggested 
similar solutions.6
Prior to national prevention efforts, a centralised statewide intervention to reduce overdose 
was initiated in 2013 in North Carolina (NC). It comprised a set of ‘bottom up’ opioid 
overdose prevention strategies implemented by community-based coalitions in conjunction 
with ‘top down’ efforts to change healthcare policies and prescriber behaviour.7 The 
intervention was coordinated by the state’s Medicaid authority, Community Care of North 
Carolina (CCNC)8 and the Mountain Area Health Education Centre (MAHEC). County-
level coalitions were invited to select and implement strategies they considered appropriate 
for their community from among those included in the ‘Project Lazarus’ model. This 
intervention model comprises seven supply, demand and harm reduction strategies (see 
online supplementary methods); pilot results showed a 69% reduction in opioid overdose in 
one NC county.9
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The seven intervention strategies are similar to national efforts, including the US Food and 
Drug Administration Risk Evaluation and Mitigation Strategies (REMS).10 The effects of 
the intervention on opioid overdose mortality and morbidity were evaluated during 2 years 
of implementation (2013 through 2014). We investigated which strategies were most 
effective and thus most promising.
METHODS
Design and setting
NC is a large state in the southeastern US, with overdose rates similar to the national 
average. An observational study was conducted to examine the effects of a centralised 
statewide intervention to reduce opioid overdose among NC residents (population 9 943 964 
in 2014). The intervention and evaluation were conducted by county (n = 100). Data were 
collected from multiple sources and aggregated at the county-month level. Statistical models 
employed an interrupted time-series approach (see online supplementary methods). All 100 
counties were included in all analyses.
Seven intervention strategies
The seven strategies in the intervention model that we provided coalitions were intended to 
be implemented together. (1) Community education promoted public awareness of 
prescription opioid overdose. (2) Provider education focused on educating medical 
professionals in chronic pain treatment, including group trainings and in-office ‘academic 
detailing,’ or tailored instruction. The NC Medical Board’s published guidelines for pain 
management were referenced in trainings.11 (3) Hospital emergency department (ED) 
policies revised hospital practices to limit ED OA prescribing and require checking the 
PDMP before prescribing. (4) Diversion control was designed to remove unused medications 
and train law enforcement on OA diversion. (5) Support programmes for patients with pain 
provided support groups, case management and pain clinic vetting and referrals. (6) 
Naloxone policies promoted the adoption of policies to disseminate the opioid antagonist 
naloxone to opioid users, first responders and caregivers. (7) Addiction treatment was 
intended to remove barriers to accessing MAT, specifically using methadone and 
buprenorphine (see table 1 in online supplementary methods).
Coalition development and support
The intervention was made available by CCNC to 84 counties in central and eastern NC, and 
by MAHEC in 16 western counties, with support from Project Lazarus, the non-profit 
organisation that developed the intervention model. When requested by coalitions, these 
organisations conducted stakeholder presentations and community forums, provided 
training, technical assistance, model ED policies and toolkits on chronic pain and addiction, 
and guided coalition development and community education. Beginning in late 2012, these 
organisations solicited applications from coalitions that demonstrated a commitment to 
adopt the intervention model. Coalitions received annual grants of $6500 to $34 400, 
supported by 12 funding organisations contributing via a coordinated mechanism (see 
Funding in online supplementary methods). Coalitions were required to implement at least 
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three of the seven strategies. Tailored materials were developed for tribal communities and 
military installations.
Intervention data
The intervention was implemented starting in March 2013. Data collection included a 
preintervention period (January 2009–February 2013) and an intervention period (March 
2013–December 2014). A dichotomous variable was constructed for each strategy by 
county-month, with ‘0’ indicating no implementation and ‘1’ indicating any implementation 
of that strategy.
Surveys of community coalition leaders and coordinators—Coalition and CCNC 
coordinator activities were monitored using retrospective biannual online surveys. Surveys 
mapped county-level implementation of each strategy. Surveys were used to ascertain 
naloxone policies, support programmes for patients with pain, ED policies, provider 
education and community education.
Addiction treatment admissions—Removing barriers to MAT was a goal of the 
intervention, with coalition messaging destigmatising these therapies and encouraging 
prescribers to become certified for office-based buprenorphine treatment. Data on drug 
treatment admissions were available from the North Carolina Treatment Outcomes and 
Programme Performance System, a quality monitoring system. Counts of new patients 
entering methadone treatment were collected from intake interviews. Using PDMP data, the 
number of new patients receiving pharmacy-dispensed oral buprenorphine for addiction 
treatment (eg, Subutex, Suboxone) was added to clinic methadone admission counts to 
create a population utilisation rate for MAT.
Diversion Control—Information concerning the location of fixed site disposal bins and 
pill take-back events was collected by surveys. Data on law enforcement trainings were 
provided by the NC State Bureau of Investigation.
Outcome data
Mortality data—Vital statistics data on overdose mortality were obtained from a public 
repository.12 ICD-10 codes were used to identify all opioid poisoning deaths with 
unintentional and undetermined intent.13 Deaths were included if the medical examiner 
attributed them to prescription opioid analgesics or illicitly manufactured opioids (eg, 
fentanyl-laced heroin) as a primary or contributing cause.
Morbidity data from EDs—Data from hospital EDs (n = 124) were obtained from the 
North Carolina Disease Event Tracking and Epidemiologic Collection Tool.1415 Visit-level 
records were abstracted using ICD-9-CM codes to identify acute opioid overdoses arising 
from all intents.16 Due to possible missing data arising from heterogeneity in data 
transmission, the proportion of injury cases without E-codes was used to adjust counts and 
standard errors.17
Alexandridis et al. Page 4
Inj Prev. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Covariate data
Since the intervention did not explicitly attempt to reduce the amount of opioids dispensed 
but rather promulgated the message that opioids should be used appropriately, OA 
dispensing rates were treated as a covariate instead of an outcome. PDMP data on all 
outpatient dispensed OA prescriptions, patients and providers were abstracted at the county-
month level. An interpolated composite value of county health factors, derived from the 
Robert Wood Johnson Foundation County Health Rankings,18 was included as a covariate to 
account for differences over time in county-level general health status. Immediate-effect, 
adjusted models also accounted for seasonal variation and detrending for secular (annual) 
effects.
Statistical models
Unadjusted average rate differences were calculated for intervention and non-intervention 
counties before and during the intervention. We used generalised estimating equations in 
scaled Poisson regression models to estimate incidence rate ratios (IRR) comparing 
intervention to non-intervention county-months, using the resident population as the offset 
(ie, denominator for rates). The number of county-months was 7200. Implementation of the 
seven strategies was modelled as dichotomous variables for each intervention. In the 
adjusted models, inclusion of all seven variables can be interpreted as the estimate of the 
effectiveness of each strategy while controlling for the implementation of the other six. 
Immediate impact models considered the effect of overdose outcomes in the same month as 
the intervention. Time-lagged regression models considered delayed impact of interventions 
by staggering outcomes 0 to 6 months after the intervention, with adjustment for opioid 
prescriptions and county health status only. Both approaches addressed mortality and 
morbidity outcomes separately.
Ethics review
This study was approved by the institutional review board of the University of North 
Carolina (IRB 12–2570).
RESULTS
General trends over the study period
The annual prevalence of unique OA patients statewide decreased by 6.9% over the study 
period, from 23.0% of all state residents in 2009 to 21.4% in 2014 (figure 1). In contrast, 
annual prescriptions dispensed for OA increased by 17.3%, from 6.22 million to 7.30 
million, an 11.4% increase (0.66 to 0.73 per person-year). The most commonly dispensed 
OAs were hydrocodone, oxycodone, codeine and morphine.
The rate of unintentional/undetermined deaths associated with all opioids increased by 
10.2% statewide over the period 2009 to 2014, from 8.1 per 100000 person-years to 9.0. The 
rate of opioid overdose-related ED visits increased by 18.6% statewide over the same period, 
from 37.4 to 44.3 per 100000 person years.
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Intervention implementation
A total of 74 out of 100 counties implemented intervention components by the end of 2014, 
covering 70% of the state population. Non-implementing counties were those that did not 
submit an application for funding or were ineligible due to a lack of resources.
Overdose mortality rates at baseline were lower in counties participating in the intervention 
than those with no direct involvement, 6.19 per 1 000 000 person-months versus 6.93, 
respectively. At the end of the observation period, average overdose death rates remained 
lower in intervention counties (6.79 vs 7.18 during the intervention period), but with a 
postintervention versus preintervention risk difference that was 0.21 per 1000000 person-
months higher in intervention counties. Initially, ED visit rates for overdose were lower in 
intervention counties than non-intervention counties at baseline, 29.7 per 1000000 person-
months versus 31.4, respectively. During the intervention period, ED visits remained lower 
in intervention counties (34.4 vs 39.4 during the intervention period). The postintervention 
versus preintervention risk difference was 3.15 per 1000000 person-months lower in 
intervention counties. However, these unadjusted rates do not take into account community 
health status, the presence of multiple interventions, secular time trends or the persistence of 
interventions, as subsequent models do.
Immediate impact of intervention
In adjusted regression models, the seven strategies were treated as independent exposures 
simultaneously, comparing implementation to no activity, adjusted for rate of OA 
prescriptions, county health status, time trends and seasonality. These models assumed an 
immediate impact of the intervention in the same month as implementation. Compared to 
unadjusted models of each strategy, adjusted models (tables 1 and 2) yielded directionally 
similar results, but adjustment resulted in IRRs closer to the null.
While most adjusted-model strategies did not have adequate precision for formal statistical 
significance, directional results were evident (figures 2 and 3). In adjusted models of 
immediate impact, healthcare provider education was associated with 9.1% (IRR 0.91; 95% 
CI 0.81 to 1.02) lower overdose mortality, but little change in overdose-related ED visits. 
Policies to limit OA dispensing in EDs were associated with 3% lower mortality (IRR 0.97; 
95% CI 0.87 to 1.07), but 6% higher overdose-related ED visits (IRR 1.06; 95% CI 1.01 to 
1.12). Naloxone policies, community education and support for patients with pain were 
associated with small increases in overdose mortality (table 1). Diversion control (IRR 1.10; 
95% CI 0.98 to 1.24) and greater use of addiction treatment (IRR 1.22; 95% CI 1.08 to 1.37) 
were associated with higher same-month mortality rates. In adjusted models of overdose-
related ED visits, same-month implementation showed small increased associations with all 
strategies (table 2).
Delayed impact of intervention
Most intervention strategies showed similar time-delayed effects as to models of same-
month impact on overdose mortality (figure 3). An exception was support programmes for 
patients with pain, which were associated with lower mortality rates in models with greater 
uptake periods after implementation. Diversion control was associated with gradual 
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increases in overdose-related ED visits after 3 months, whereas naloxone policies were 
associated with gradual decreases at 5 and 6 months. Addiction treatment utilisation showed 
the greatest time-lagged effect, with significantly lower ED visits in models with 2 to 5 
months of outcome lag (greatest reduction at 4 months; IRR 0.86, 95% CI 0.81 to 0.91), but 
returning to the null at 6 months.
DISCUSSION
We sought to evaluate which of the seven prevention strategies that constituted the Project 
Lazarus model most effectively reduced opioid overdose. Prescriber education concerning 
pain management and addiction, and ED policies limiting OA prescribing and encouraging 
PDMP checks, had the greatest, though modest and not statistically significant, immediate 
impact on mortality. MAT, in the form of buprenorphine and methadone, showed gradual 
reductions in overdose-related ED visits after 2 to 5 months of uptake. While this effect of 
MAT on ED visits is consistent with prior epidemiological studies19 and meta-analyses,20–22 
our findings extend current knowledge by demonstrating that reductions in overdose may be 
persistent even after controlling for other interventions. However, MAT was associated with 
increased overdose mortality in both immediate-impact and delayed-impact models, which 
differed from previous findings.23 These divergent results, and the persistent magnitude of 
the association in our lagged models, suggest that the populations that use MAT are not the 
populations contributing excess mortality.
While community coalition-based interventions have not been uniformly prioritised as 
national policy, our experience in NC suggests the critical role that coalitions can play in 
promoting the prominence of the overdose issue and improving sustainability of 
interventions.24 While no immediate impact on overdose was observed from diversion 
control, naloxone policies or community education, these strategies were intended to 
broaden the base of stakeholders involved in the initiative, and were particularly important 
for engaging law enforcement, pharmacists, faith communities and schools.2526
Study results are expected to generalise to other areas of the country because efforts to 
reduce overdose are now present in every state. Studies of a five-strategy intervention to 
reduce OA overdose deaths in Staten Island (New York City), which emphasised 
promulgating pain treatment guidelines, documented a 29% decline in overdose deaths from 
2011 to 2013 and changes in OA prescribing, although it did not attempt to isolate the 
impact of individual strategies, nor did it focus on addiction treatment.2728 A comprehensive 
opioid utilisation programme instituted by a health insurance provider in Massachusetts 
showed declines in opioid prescribing.29 Patient support and education programme have also 
been shown to be effective.3031 Considered collectively, these studies reinforce findings that 
a multimodal approach with medical and community components may offer solutions for 
reducing overdose.
Previous research has demonstrated reductions in mortality after the implementation of take-
home naloxone programme.2332 However, the strategy evaluated in this analysis was limited 
to the development of policies to encourage take-home naloxone, not actual reversals, and 
thus may take longer to demonstrate an effect than the time period under analysis. State 
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legislation removing legal barriers to naloxone distribution was enacted in April 2013; while 
subsequent local policies took the form of standing orders from local health departments and 
training of law enforcement to use naloxone, uptake was limited. During the study period, 
the largest naloxone distribution programme, implemented by the North Carolina Harm 
Reduction Coalition, was starting, but reported 242 reversal events by the end of December 
2014 (R Childs, personal communication, NCHRC, 2015). Because most reversals were 
clustered in a handful of cities and involved predominantly heroin overdoses, the reversal 
count was too geo-temporally sparse to incorporate into models. Project Lazarus encouraged 
naloxone co-prescribing, distributed kits that contained educational materials and 
disseminated trainings and toolkits. Physicians reported overdose reversals in social media 
during the study period from addiction treatment programme, but due to the decentralised 
nature of naloxone distribution, records of reversals were not systematically documented.
The statewide effort to address the opioid crisis fostered unprecedented collaboration 
between stakeholders, and afforded the opportunity to bring together disparate secondary 
data sources into a single evaluation framework. The results constitute one of the nation’s 
largest observational evaluations of coalition effectiveness. An earlier review found that only 
10 of 34 studies reported improvements in community health that could be attributed with 
confidence to coalition activity.33 Caution must be used in assigning causality to the efforts 
of the coalitions, due to the lack of an experimental design in this study.
While intervention counties consistently had lower overdose rates than non-intervention 
counties, there was an increase in the absolute number of opioid overdoses statewide, similar 
to national trends.1 An increase in heroin overdose deaths was noted during the study period,
34
 which may be due in part to reductions in the supply of diverted OA, although the data we 
collected do not address this issue. In the pilot implementation,9 an absolute reduction in 
overdose deaths took 3 years to manifest, suggesting that continued monitoring is warranted.
Study limitations
The study’s greatest limitation was our inability to control for allocation of the intervention 
due to funder priorities and the voluntary nature of funding applications. As a result, 
uncontrolled or residual confounding may be present. Measures with temporal and 
geographic specificity were not accessible for factors suspected to affect overdose rates or 
coalition effectiveness: fluctuations in heroin purity and the proliferation of fentanyl-heroin, 
law enforcement arrests, quality of coalition leadership,35 history of collaboration among 
organisations,36 PDMP query rates by prescribers37 and commercial health insurer policy 
changes.29 Our models necessarily assumed the effect of these potential confounders to be 
non-differential. Similarly, we assumed that the REMS had no differential impact on county 
outcomes since they were intended to be implemented uniformly, were not fully 
implemented during the study period38 or only applied to very limited numbers of 
prescriptions.39 In addition, there may have been ‘contamination’ of effects and outcomes 
across adjacent counties and residual misclassification bias from non-reporting sites. The 
effect of prescriber education and law enforcement trainings may have been attenuated in 
models because the exact location of each attendee was not available, and the training was 
allocated to the county in which it was conducted. Data on the use of naltrexone for opioid 
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addiction were not available, and should be considered in future studies. The use of 
dichotomously coded exposures was necessitated by both the goals of the analysis and the 
nature of the survey data (see online supplementary methods). Finally, in the original pilot 
study of the Project Lazarus model, the strongest effects were observed after 3 years of 
implementation. A longer observation period of the statewide implementation may provide 
stronger evidence of the effects.
Mortality data have inherent flaws,40 mainly lack of specificity of both substances and 
intent. Despite these shortcomings, overdose deaths were analysed because they were the 
primary target of the interventions and vital statistics are the standard source. NC medical 
examiners have a standardised methodology for causal attribution of overdose, using death 
scene investigation reports, PDMP data, medical records, interviews and postmortem 
toxicology assays that do not rely solely on the presence of opioid or predetermined 
concentration thresholds.
CONCLUSIONS
These findings provide guidance as to which strategies may be most effective in reducing 
opioid overdose. Among the seven strategies, prescriber education and hospital ED policies 
showed modest immediate reductions in mortality, whereas addiction treatment showed 
beneficial effects in reducing ED-related overdose visits in time-lagged models, despite an 
unexpected adverse association with mortality. Future research should consider experimental 
designs, the resources available to communities and the universe of available data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What is already known on this subject
► Opioid analgesic overdoses have increased in the US for over 20 years.
► In response, policy has focused on prescriber education and on supply, 
demand and harm reduction strategies.
What this study adds
► 74 of 100 North Carolina counties adopted the Project Lazarus model, 
comprised of seven distinct overdose prevention strategies, with funding 
beginning in 2013.
► Prescriber education related to pain management and addiction treatment, 
and emergency department (ED) policies limiting opioid dispensing showed 
modest immediate reductions in mortality (9% and 3%, respectively).
► Medication-assisted treatment expansions showed beneficial effects in 
reducing ED-related overdose visits in time-lagged models (up to a 14% 
reduction), despite an unexpected adverse association with mortality (a 22% 
increase).
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Figure 1. 
Monthly counts of outcomes before and during intervention, North Carolina, 2009–2014. 
Statewide, monthly counts of outpatient opioid analgesic (OA) prescriptions dispensed, 
opioid overdose mortality and overdose-related hospital emergency department (ED) visits. 
In subsequent modelling, OA prescriptions dispensed was treated as a covariate, while 
overdose was the outcome variable. Grey triangles represent the pre-intervention period used 
in models (January 2009 to February 2013) and the black dots represent the intervention 
period (March 2013 to December 2014). By the end of the intervention period, the 
intervention was implemented in 74 of 100 counties, representing 70% of the total 
population.
Alexandridis et al. Page 13
Inj Prev. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Effects of implementing intervention strategies on overdose mortality and overdose-related 
emergency department (ED) visits. The outcome for A and B are overdose mortality and 
overdose-related ED visits, respectively. Results from multivariate regression models 
considered all seven intervention strategies simultaneously, after adjusting for the rate of 
opioid analgesic prescriptions, county health status, annual trends and seasonality. The 
models used to generate the figures used 0 for the referent group, and 1 for the 
implementation of the strategy, with indicator coding. IRRs (tables 1 and 2) were converted 
to percent change, represented by open circles. The horizontal bars are the model-based 95% 
CI. The grey vertical line represents the null.
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Figure 3. 
Effects of implementing intervention strategies in time-lagged regression models of delayed 
impact of intervention.The vertical axis is percent change in overdose rates between 
intervention and non-intervention counties; the outcome in A is overdose mortality and B is 
overdose-related emergency department (ED) visits. Results from time-lagged (0 to 6 
months) multivariate regression models considered all seven intervention strategies 
simultaneously, after adjusting for the rate of opioid analgesic prescriptions and county 
health status. AT, greater utilisation of addiction treatment; CE, community education; DC, 
diversion control; NP, take-home naloxone policies; PE, prescriber education on pain 
management and addiction; PP, support programme for patients with pain.
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